10-Q: Cibus Reports Q3 2026 Results, Faces Going Concern Doubt

Cibus, Inc. filed its Q3 2026 10-Q, showing revenue growth but also significant operating losses and a stated substantial doubt about its ability to continue as a going concern.

Summary

• Cibus, Inc. reported its third-quarter 2026 financial results, highlighting revenue of $0.8 million, an increase from $0.6 million in the prior year's quarter.
• The company incurred a net loss of $21.9 million for the quarter, compared to a net loss of $24.3 million in the same period last year.
• For the nine months ended September 30, 2026, revenue was $3.5 million, up from $2.6 million in the prior year, while the net loss was $65.3 million, an improvement from $100.3 million in the prior year.
• The company has an accumulated deficit of $923.6 million as of September 30, 2026.
• Cibus explicitly states substantial doubt about its ability to continue as a going concern within one year due to its financial condition, requiring additional capital to sustain business plans.
• Cost-saving initiatives have been implemented, with an expected annual net cash usage run-rate of approximately $35.0 million exiting 2026.
• The company is focusing on its Rice and Sustainable Ingredients programs, with ongoing discussions for commercialization agreements and product development.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the company's continued significant losses, substantial accumulated deficit, and the explicit statement of substantial doubt about its ability to continue as a going concern, despite some revenue growth and cost-saving measures.

Positives

• Revenue increased by 30% to $0.8 million in Q3 2026 compared to Q3 2025.
• Revenue for the nine months ended September 30, 2026, increased by 35% to $3.5 million compared to the same period in 2025.
• Net loss for Q3 2026 decreased by 10% to $21.9 million compared to $24.3 million in Q3 2025.
• Net loss for the nine months ended September 30, 2026, decreased by 35% to $65.3 million compared to $100.3 million in the same period of 2025.
• Research and development expenses decreased by 27% in Q3 2026 and 28% for the nine months ended September 30, 2026, reflecting cost-saving measures.
• Selling, general, and administrative expenses decreased by 27% for the nine months ended September 30, 2026.
• The company has implemented cost-saving initiatives and expects an annual net cash usage run-rate of approximately $35.0 million exiting 2026.
• Progress is being made in the Rice herbicide tolerance program with field trials and ongoing negotiations for commercialization agreements.

Negatives

• The company has an accumulated deficit of $923.6 million as of September 30, 2026.
• Substantial doubt is raised about the company's ability to continue as a going concern within one year.
• The company requires additional capital in the near term to sustain its business plans.
• Net loss for Q3 2026 was $21.9 million, and for the nine months ended September 30, 2026, was $65.3 million.
• Cash and cash equivalents were $10.7 million as of September 30, 2026, against current liabilities of $13.9 million.
• The company's ability to continue as a going concern depends on obtaining additional financing, which is not guaranteed.
• If additional capital is not raised, the company may have to implement more stringent cost reductions, delay, scale back, or cease operations.
• The Royalty Liability - Related Parties balance was $263.4 million as of September 30, 2026.

Risks

• The company's need for additional near-term funding to finance its activities and challenges in obtaining additional capital on acceptable terms, or at all.
• The company's ability to continue as a going concern within one year from the issuance of these condensed consolidated financial statements.
• The risk that the company may have to implement additional, more stringent cost reduction measures to manage liquidity, or significantly delay, scale back, or cease operations.
• The potential for substantial dilution to existing stockholders and increased fixed payment obligations if additional funds are raised through the issuance of debt or equity securities.
• The company's reliance on third parties in connection with its development activities and for commercialization.
• Challenges associated with the company's ability to effectively license its productivity traits and sustainable ingredient products.
• The risk that farmers do not recognize the value in germplasm containing the company's traits or that farmers and processors fail to work effectively with crops containing the company's traits.
• Delays or disruptions in the company's platform or trait product development efforts.

Future Outlook

Cibus expects to continue generating losses for the next several years and anticipates needing to raise additional capital to support its business plans. The company expects an annual net cash usage run-rate of approximately $35.0 million exiting 2026. Future cash needs are expected to be financed through cash on hand, commercialization activities, government or third-party funding, public or private equity or debt financings, or a combination thereof. The company's ability to continue as a going concern is dependent on its ability to secure additional financing.

Management Comments

• Cibus has taken a series of cost cutting initiatives designed to streamline its cost structure, however, Cibus will need to raise additional capital to support its business plans and successful execution of these plans is not within the Companys control.
• If the Company is unable to raise additional capital in a sufficient amount or on acceptable terms, the Company may have to implement additional, more stringent cost reduction measures to manage liquidity, and the Company may have to significantly delay, scale back, or cease operations, in part or in full.
• Cibus' Board of Directors continues to evaluate a full range of strategic alternatives to maximize stockholder value.
• The Company believes that its cash and cash equivalents as of September 30, 2026, is not sufficient to fund its operations for a period of 12 months or more from the date of this filing.
• Cibus expects that its existing cash and cash equivalents is sufficient to fund planned operating expenses and capital expenditure requirements into early in the first quarter of 2027, reflecting current cash usage expectations.

Industry Context

StockSavvy.ai notes that Cibus operates in the rapidly evolving agricultural biotechnology sector, focusing on gene editing for crop improvement. The company's approach of making precise improvements to a plant's own genes, without adding foreign DNA, aims to navigate regulatory pathways more efficiently than traditional GMOs, particularly in jurisdictions like the EU with its new NGT rules. However, the industry faces challenges related to long development cycles, significant R&D investment, and complex global regulatory landscapes.

Comparison to Industry Standards

• The filing mentions that a 2022 study for CropLife International estimated GMO trait development costs at $115.0 million and timelines of 16.5 years from discovery to commercialization, with regulatory work being the longest phase.
• Cibus' proprietary Direct Breeding SM system aims to significantly reduce these timelines and costs by utilizing gene editing on a plant's own genes, with traits regulated as conventionally bred crops in key jurisdictions.
• The company's focus on productivity traits (yield improvement, input reduction, resilience) and sustainable ingredients aligns with broader industry trends towards more sustainable and efficient agricultural practices.
• The regulatory landscape for gene editing is evolving, with the EU's new NGT rules aligning with conventional breeding for certain edits, a significant development compared to previous stringent GMO regulations.

Legal Proceedings

• In September 2026, the landlord of the company's Roseville, Minnesota facility initiated litigation alleging breach of the lease agreement for nonpayment of rent. The company has recognized its contractual lease obligations and applicable related charges, and does not expect the resolution to result in a material loss in excess of amounts already recognized.

Related Party Transactions

• Royalty liability - related parties balance was $263,362,000 as of September 30, 2026, and $234,923,000 as of December 31, 2025.
• Royalty liability interest expense - related parties was $9.8 million for the three months ended September 30, 2026, and $28.4 million for the nine months ended September 30, 2026.

Stakeholder Impact

• Existing stockholders face potential dilution if the company raises additional capital through equity issuances.
• The company's ability to continue as a going concern directly impacts all stakeholders, including employees, investors, and partners.
• Creditors and suppliers may face uncertainty regarding the company's ability to meet its financial obligations if additional funding is not secured.
• Partners and customers in Rice and Sustainable Ingredients programs may experience delays or changes in project timelines if the company faces severe liquidity constraints.

Next Steps

• Continue negotiations toward a definitive commercialization agreement with Interoc for Rice herbicide tolerance traits, targeting an initial commercial launch as early as 2028.
• Prepare a trait regulatory dossier for authorization to import Rice trait material into Brazil.
• Continue discussions with additional seed companies in Latin America and India for Rice traits.
• Advance manufacturing processes for anticipated biofragrance production runs.
• Evaluate additional fragrance ingredients in development using proprietary technology and process.
• Continue advancing a partially partner-funded sustainable ingredients program in Soybean.
• Transfer nutrient-use efficiency edited Canola seed lines to the John Innes Centre for evaluation in the fourth quarter of 2026.
• Begin the nutrient-use efficiency edit in Rice.

Key Dates

Recommendation

The filing presents significant financial distress, including substantial operating losses, a large accumulated deficit, and an explicit statement of substantial doubt about the company's ability to continue as a going concern. While there are positive developments in revenue growth and cost management, these are overshadowed by the immediate need for substantial capital raises and the inherent risks associated with such financing and the company's operational viability. The current financial situation and going concern risk suggest a high probability of significant negative future events for shareholders.

Keywords

gene editing, plant traits, agriculture technology, sustainable ingredients, rice, canola, royalty, biotechnology